TB vaccine challenge study pulled before it began
NCT ID NCT06845358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if the BCG vaccine, given as a skin injection, could stop the TB bacteria from growing in healthy adults. Researchers planned to vaccinate some volunteers and then expose them to a weakened form of TB six months later to measure protection. However, the trial was withdrawn before any volunteers were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BCG TICE strain (a live, weakened tuberculosis vaccine)
- What this could lead to
- If successful, this study could help researchers understand how well the BCG vaccine protects against TB infection, potentially guiding future vaccine development.
- What could go wrong
- This trial was withdrawn before any participants enrolled, so no data was collected. The approach is very early-stage and may not translate to real-world protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune profiling unlock the hidden stages of tuberculosis?
- Could inhaled TB drugs curb the spread of Drug-Resistant tuberculosis?
- Can new tests predict who will develop active TB?
- Could a 3-Month TB cocktail replace the standard 6-Month regimen?
- Could a simple blood test ensure the right TB dose for kids?
- Community-Driven TB screening aims to reach vulnerable immigrants